Definium Therapeutics, Inc. (Nasdaq:
DFTX) has priced an upsized underwritten public offering of 20,588,236 common shares at $34.00 per share, raising approximately $700 million in gross proceeds.
Definium granted underwriters an option for 30 days to purchase up to an additional 3,088,235 common shares at $34.00 per share, less underwriting discounts and commissions.
The net proceeds will be used for research and development of product candidates, preparation for the potential commercialization of DT120 ODT (if approved), and general corporate purposes and working capital.
The offering is expected to close on or about June 25, 2026, subject to customary closing conditions.
Sources:
Definium Therapeutics prices $700M upsized public offering at $34.00
Definium prices $700M public offering - DFTX - Stock Titan
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
Definium Therapeutics (DFTX) Launches $500M Public Offering to F
Why Definium Therapeutics (DFTX) Is Up 49.8% After DT120 Phase 3 Win And $700 Million Raise
Definium Therapeutics (DFTX) offers $500M in shares and pre ...
DFTX - Definium Therapeutics Inc Stock Price and Quote - Finviz
Definium Therapeutics Prices Upsized $700 Million Share Offering
Definium Therapeutics Inc, DFTX:NSQ summary - FT.com
Definium Therapeutics Aims for $500M Public Offering
MindMed Rebrands to Definium Therapeutics, Advancing ... - SEC.gov